Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 54

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 54
---
uable upon the exercise of options that are exercisable within 60 days of March 27, 2025 with the remainder vesting in the month subsequent the 60 days from March 27, 2025 and (c) 14,829 shares of common stock held by the Eric I. Richman Living Trust. Mr. Richman is the trustee for the Eric I. Richman Living Trust and has sole voting and investment power over the shares held by the Eric I. Richman Living Trust. |

| (4) | Consists of (a) 880,784 shares of common stock held by 1 MM & 1 PP AG, of which Dr. Islam is the ultimate shareholder and beneficial owner, (b) 50,000 shares of common stock held by Dr. Islam, and (c) 67,520 shares of common stock, held in Dr. Islam’s individual name, issuable upon the exercise of options granted to Dr. Islam that are exercisable within 60 days of March 27, 2025. |

| (5) | Consists of shares of common stock issuable upon the exercise of options that are exercisable within 60 days of March 27, 2025. |

| (6) | Consists of (a) 30,000 shares of common stock held by Mr. Riley, (b) 80,732 shares of common stock issuable upon the exercise of options that are exercisable within 60 days of March 27, 2025. |

| (7) | Consists of (a) 27,524 shares of common stock held by Mr. Alder and (b) 30,750 shares of common stock with respect to vested RSUs without consideration of any requirements or conditions that need to be satisfied for such shares to be issued. Upon Mr. Alder’s termination of employment with the Company effective as of June 25, 2024, a portion of his RSU awards (30,750 units) were accelerated to vest and the remainder of the unvested RSU awards (40,126 units) were forfeited. As of March 27, 2025, shares of common stock had not been issued in respect of the vested RSUs. The RSU awards were granted under the 2022 Plan. |

| (8) | Consist of (a) 1,224,742 shares of our common stock held by our directors and current executive officers, (b)